Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes

DE-WEI SONG**, NIAN XIN†, BING-JIE XIE‡, YU-JUAN LI†, LING-YAN MENG†, HONG-MEI LI‡, MICHAEL SCHLÄPPI§ and YU-LIN DENG†

†School of Life Science, Beijing Institute of Technology, Beijing 100081; ‡Division of Chemical Metrology and Analytical Science, National Institute of Metrology, Beijing 100013, P.R. China; §Marquette University, Milwaukee, WI 53233, USA

Received September 2, 2013; Accepted December 16, 2013

DOI: 10.3892/ijmm.2013.1604

Abstract. There are statistical data indicating that diabetes is a risk factor for Parkinson's disease (PD). Methylglyoxal (MG), a biologically reactive byproduct of glucose metabolism, the levels of which have been shown to be increase in diabetes, reacts with dopamine to form 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ); this formation may provide further insight into the connection between PD and diabetes. In this study, we investigated the role of ADTIQ in these two diseases to determine in an aim to enhance our understanding of the link between PD and diabetes. To this end, a cell model of hyperglycemia and a rat model of diabetes were established. In the cell model of hyperglycemia, compared with the control group, the elevated glucose levels promoted free hydroxyl radical formation (p<0.01). An ADTIQ assay was successfully developed and ADTIQ levels were detected and quantified. The levels of its precursors, MG and dopamine (DA), were determined in both the cell model of hyperglycemia and the rat model of diabetes. The proteins related to glucose metabolism were also assayed. Compared with the control group, ADTIQ and MG levels were significantly elevated not only in the cell model of hyperglycemia, but also in the brains of rats with diabetes (p<0.01). Seven key enzymes from the glycolytic pathway were found to be significantly more abundant in the brains of rats with diabetes. Moreover, it was found that adenosine triphosphate (ATP) synthase and superoxide dismutase (SOD) expression levels were markedly decreased in the rats with diabetes compared with the control group. Therefore, ADTIQ expression levels were found to be elevated under hyperglycemic conditions. The results reported herein demonstrate that ADTIQ, which is derived from MG, the levels of which are increased in diabetes, may serve as a neurotoxin to dopaminergic neurons, eventually leading to PD.

Introduction

Diabetes mellitus (DM), as a state of chronic hyperglycemia, and Parkinson's disease (PD) are diseases which consist a global health threat. In recent years, there have been increasing data indicating that hyperglycemia is associated with an increased risk of developing PD (1,2). However, the mechanisms underlying the association between hyperglycemia and PD have not yet been elucidated.

Deng and Rajput (6) were the first to report, in 2001, that 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ), a salsolinol-like compound, is found at highly concentrated levels in the brains of patients who suffer from PD (3). When the brains of deceased patients with PD were compared to those of normal subjects, it was found that patients with PD presented elevated levels of ADTIQ in all the examined brain areas. This finding indicated that elevated ADTIQ expression levels may be one of the mechanisms involved in the increased risk patients with diabetes have of developing PD (4).
ADTIQ is an endogenous product acquired by a reaction between methylglyoxal (MG) and dopamine (DA). The reactive α-keto-aldehyde MG is the most important carbonyl, formed endogenously as a byproduct of the glycolytic pathway and formed either by the degradation of triosephosphates, or non-enzymatically by sugar fragmentation reactions (5). MG is gradually accumulated under hyperglycemic conditions, which may induce oxidative stress (6).

The neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), is known to deplete striatal DA and to cause neuronal degeneration of the nigrostriatal pathway when administered to humans. The reason behind this, is that MPTP may induce oxidative stress and mitochondrial dysfunction, which can lead to PD (7). Catechol isoquinolines (CIQs) are considered to be naturally occurring MPTP-like neurotoxins. Salsolinol is demonstrated to be formed from DA and acetaldehyde by an (R)-salsolinol synthase-mediated condensation, N-methylated into (R)-N-methylsalsolinol by a neutral (R)-salsolinol N-methyltransferase, and then oxidized into an ion of 6,7-dihydroxy-1,2-dimethyl-isoquinolium, an analogue of 1-methyl-4-phenyropyridinium (MPP+). The toxicity of N-methylsalsolinol and its oxidation product for dopaminergic neurons has previously been examined in vivo and in vitro (8,9).

The chemical structure of ADTIQ is very similar to that of salsolinol (Fig. 1). Therefore, in the current study, we hypothesize that ADTIQ may be another endogenous neurotoxin with a possibly negative effect on the nervous system, which may cause damage to the peripheral, automatic and central nervous systems, and may ultimately lead to PD.

In the present study, ADTIQ levels and those of its precursor, MG, were examined in a cell model of hyperglycemia and a rat model of diabetes. Proteomics was used to analyze the proteins involved, also analyzing their role in glucose metabolism.

Materials and methods

Cell line. The parental SH-SY5Y human neuroblastoma cell line was provided by Professor Wei-Hong Song (University of British Columbia).

Animals. The study complied with the ‘Guide for the Care and use of Laboratory Animals’ published by the US National Institutes of Health (NIH publication no. 85-23, revised in 1985) and all animal experiments were approved by the Institutional Animal Research Advisory Committee of the Beijing Institute of Technology. Wistar rats (male, 180–200 g body weight, 6-8 weeks old) and their granular food were provided by the Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (Beijing, China). The animals were maintained under a 12-h light/dark cycle at approximately 24±1°C and were allowed free access to food and water.

Cell culture and establishment of the rat model of diabetes. The SH-SY5Y cells were grown under standard conditions in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM L-glutamine and 10% fetal calf serum at 37°C (5% CO2).

A total of 40 Wistar rats were randomly divided into 2 groups, a control group and a diabetes model group (10 rats in the control group and 30 rats in the model group). Baseline blood glucose levels of all animals were measured after 12 h of fasting. Diabetes was induced by a single intraperitoneal injection of prepared streptozotocin (60 mg/kg body weight; Sigma, St. Louis, MO, USA) dissolved in sterile saline (0.85% NaCl). The control rats received an equal volume of the vehicle (normal saline). Non-fasting blood glucose levels were quantified a week later with the use of a commercially available glucometer. Streptozotocin-injected rats whose initial blood glucose levels were <300 mg/dl were considered as non-diabetic. Non-fasting blood glucose levels were monitored every 7th day during the course of the study and were examined again right before all the rats were anesthetized. The model group was fed for 18 weeks in order to imitate chronic hyperglycemia induced by long-term injury to the nervous system.

Measurement of free hydroxyl radicals in SH-SY5Y cells by high-performance liquid chromatography (HPLC)-electrochemical detector (ECD) assay. The SH-SY5Y cells were exposed to 60 mM glucose (10). After 48 h, the cells were harvested and 200 µl 10 mM ortho-oxybenzoic were added to the cells. The cells were lysed by sonication (50 cycles of 10 sec), centrifuged at 16,000 x g (4°C, 10 min) following incubation with 0.4 M PCA (1:2:v:v) for 30 min, and passed through a 0.22-µm filter membrane prior to analysis. All these samples were analyzed by HPLC-ECD using a CoulArray Electrochemical Detector (Model 5600A; ESA, USA) under the following conditions: i) the organic phase consisted of 10% methanol diluted in water (solvent A); ii) the balanced solution contained 35 mM citric acid, 45 mM sodium acetate, 0.13 mM Na2EDTA, 0.2 mM SHS water-solution, pH 4.0 (solvent B); while iii) for the stationary phase, Alltima C18 (4.6x150 mm, 5 µm) analytical column was used. The column had a flow rate of 1 ml/min, it reached a temperature of 30°C, while its electric potential was: -50, 50, 300, 450, 650, 780, 900 mV. The volume of the sample used was 40 µl.

Detection of MG and ADTIQ in hyperglycemic cells and rats with diabetes by liquid chromatography (LC)-mass spectrometry (MS). LC-MS for the detection of MG and ADTIQ was carried out as previously described (11,12). The prepared cells and brain tissues were lysed by sonication (50 cycles of 10 sec)

Figure 1. Reactions of methylglyoxal and aldehydes with dopamine (DA). The chemical structure of 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) is very similar to that of salsolinol. (A) DA reacts with methylglyoxal to produce ADTIQ; (B) DA reacts with aldehyde to produce salsolinol.

A

DA

Methylglyoxal

ADTIQ

B

DA

Aldehyde

Salsolinol

MG
and centrifuged at 16,000 x g (4°C, 10 min) following incubation with 0.4 M PCA (1:2/v:v) for 30 min. The supernatant was passed through a 0.22-µm filter membrane. O-phenylendiamine (2 mM) was added to the samples followed by incubation for 1 h at 37°C. As MG cannot be retained on C₄ columns, an indirect derivatization method was used to measure MG levels in the rat brains. MG reacted with o-phenylendiamine and the product, 2-methylquinoline (2-MQ), was detected as a measure of MG content. Tissue samples were separated into 2 groups, one for derivatization and another for no derivatization.

LC was performed with the discovery F5-SH column (4.6x250 mm, 5 µm). The mobile phase consisted of 32% methanol and 68% formic acid (pH 3.49), while the flow rate was 0.7 ml/min and the UV detection wave length 315 nm. The volume of the sample analyzed was 50 µl. Mass spectrum analysis was performed under the following conditions: mode electrospray ionization (ESI), positive ion mode; MS scanning; nebulizer pressure, 28 psi; drying gas flow rate, 8 l/min; scanning range, 135-225 m/z; and extracted ion chromatography (EIC), 145 (2-MQ) and 208 (ADT IQ).

**Protein extraction and trypsin digestion.** The control and model rat brain specimens were prepared and lysed by sonication (50 cycles of 10 sec) in 300 µl lysis buffer [8 M urea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS), 10 mM dithiothreitol (DTT) and 0.09 g solid urea]. The homogenates were left at room temperature for 1 h after having been centrifuged at 20,000 x g for 60 min at 4°C, and the supernatants were then collected as protein extracts. Protein concentration was determined by the Lowry method after dialysis. Proteins (500 µg) were freeze-dried at -56°C under a vacuum, as previously described (13,14).

Desiccated proteins were dissolved in 200 µl buffer solution (8 M urea, 10 mM DTT and 50 mM NH₄HCO₃) and incubated at 37°C for 4 h. Subsequently, 5 µl of iodoacetamide (1 M) were added in order for the alkylation reaction to occur in the dark for 1 h. The urea concentration was diluted in 500 µl NH₄HCO₃ (50 mM). Porcine trypsin (Promega, Madison, WI, USA) was added in a final enzyme to protein ratio of 1:20. Digestion was conducted at 37°C for 18 h.

**Peptide detection and quantification by LC-ESI-time-of-flight (TOF) MS.** The quantification of the peptide mixtures in limited amounts of rat brain tissues was carried out by LC-ESI-TOF-MS (Agilent 6210 Time-of-Flight LC/MS System; Agilent Technologies, Inc., Santa Clara, CA, USA). Samples were separated by a C₁₈ column (4.6x250 mm, 5 µm) in acetonitrile-0.1% formic acid (5:95) (mobile phase) with a flow rate of 0.8 µl/min for online enrichment. They were then analyzed by a Zorbax C₁₈ column (0.5x150 mm, 5 µm). The peptides were separated and analyzed completely within 70 min. The ESI positive scanning range was 300-1,800 m/z.

**Analysis of peptides by LC-MS/MS.** The peptide mixtures were separated by chromatography and analyzed by ion trap mass spectrometry (Agilent 1100 series LC/MSD mass spectrometer; Agilent Technologies, Inc.) with the reversed-phase (RP) C₁₈ column (4.6x250 mm, 5 µm), at a flow rate of 0.8 ml/min. Samples of proteolytic digestes (80 µl) were injected into the column and run with a linear gradient of 95% solvent A (0.1% formic acid) to 100% solvent B (acetonitrile) for a time period of 70 min and post run for another 10 min (14).

**Bioinformatics analysis.** MassHunter and MassProfiler, analysis software provided by Agilent Technologies, Inc. were used in order to analyze the TOF data. Significantly differentially expressed peptides were selected from the mass data. The same samples were analyzed by LC-TOF before they were validated by LC-MS/MS. The m/z value of significantly differentially expressed peptides was preferentially selected for LC-MS/MS analysis.

Trypsin cleaves proteins at the C terminus of lysine and arginine residues, thereby generating a peptide mass fingerprint (PMF) that can be used to search databases. The MS/MS data were searched using the MASCOT tool (http://www.matrixscience.com; Matrix Science, London, UK). The threshold parameter values for mass accuracy were 150 ppm and one miscleavage was allowed. The search was performed against rat protein sequences. PMFs from our samples were compared to corresponding fingerprints from NCBInr (http://ncbi.nih.gov/National Center for Biotechnical Information, Bethesda, MD, USA), MSDB (csc-fserve.hh.med.ic.ac.uk/msdb.html;Proteomics Department, Hammersmith Campus, Imperial College, London, UK) and EnsemblC (http://www.ensembl.org/Sanger Centre, Hinxton, UK) databases in order to find matches with the virtual tryptic protein masses. Gene Ontology entries were retrieved based on the IPI data files from Swiss-Prot. Gene Ontology terms were mapped to Ontoglyph terms (http://6l.50.138.18/GOfact/) to provide a coarse-grained classification of gene function (15).

**Detection of protein content by western blot analysis.** Brain homogenate expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and adenosine triphosphate (ATP) synthase were determined by western blot analysis. First, the proteins were separated by SDS-PAGE, then electrotransferred (electrodes were attached and the power supply was set to 100 V at constant voltage for 1 h at 4°C). Finally, immunodetection was carried out as follows: the membranes were stained, blocked and washed, and then subjected to first antibody and second antibody and detection for the target protein.

**Statistical analysis.** SPSS 13.0 software (SPSS, Chicago, IL, USA) was used for statistical analysis. Values are expressed as the means ± standard deviation (SD). Data were analyzed using one-way ANOVA, followed by a Student's two-tailed paired t-test for comparisons between 2 groups. A P-value <0.05 was considered to indicate a statistically significant difference.

**Results**

**Measurement of free hydroxyl radicals in hyperglycemic SH-SY5Y cells.** Salicylic acid hydroxylation is a specific scavenger for free hydroxyl radicals. Thus, the hydroxylation products, 2,3-dihydroxybenzoic acid (2,3-DHBA) and 2,5-dihydroxybenzoic acid (2,5-DHBA), were measured in order to indirectly evaluate the degree of oxidative stress (16). Free hydroxyl radicals in the SH-SY5Y cells treated with or without glucose were measured by HPLC-ECD assay. No
2-MQ represented the amount of methylglyoxal by western blot analysis in order to control group. 2-MQ and ADTIQ expression, of hyperglycemia by HPLC. Thus, the comparison cultured under hyperglycemic conditions means ± standard deviation (SD). That CIQs, ed-cells are expressed as the following a SH-SY5Y cells. Compared with control group, the GAPDH content in the control group, we observed a significant increase in the expression levels of ADTIQ in the neuronal SH-SY5Y cells cultured under hyperglycemic conditions following a 2-h incubation period (p<0.01) (Fig. 3).

Measurement of ADTIQ levels in the cell model of hyperglycemia. Only minimal amounts of ADTIQ were detected in the control group, contrary to the large amount that was detected in the cells treated with a final concentration of 60 mM glucose for 2 h. Compared with the control group, we observed a significant increase in the expression levels of ADTIQ in the neuronal SH-SY5Y cells cultured under hyperglycemic conditions following a 2-h incubation period (p<0.01) (Fig. 3).

Measurement of MG and ADTIQ levels in the brains of rats with diabetes. The abundance of MG can be indirectly determined by measuring the levels of 2-MQ (17). LC/MS analysis was conducted to determine whether ADTIQ accumulated in the brains of rats with diabetes. The results indicated that the brains of rats with diabetes had significantly higher levels of ADTIQ (p<0.01) compared with the control group (Fig. 4).

Measurement of relative protein levels in rat brains. A proteomics approach was used to search for differentially expressed proteins in the brains of rats with diabetes (Materials and methods). The results of this proteomics and bioinformatics analysis revealed that, in comparison to the control group, the expression levels of 7 key enzymes from the glycolytic pathway were significantly increased in the brains of rats with diabetes, while the levels of ATP synthase, an enzyme from the oxidative phosphorylation pathway, and of those superoxide dismutase (SOD) were significantly decreased. Compared with the control group, the diabetes group had a higher rate of glycolysis and a lower rate of oxidative phosphorylation (Table I).

Two proteins, GAPDH and ATP synthase, were selected to be semi-quantified by western blot analysis in order to verify the reliability of the proteomics results. It was shown that, compared with the control group, the GAPDH content in the rats with diabetes was increased while the ATP synthase content was decreased. These results were consistent with the those from proteomics analysis. Thus, the comparative proteomics analysis proved to be a feasible and reliable approach for studying relative protein levels (Fig. 5).

Discussion

The pathological process of PD is complex, involving a number of different factors, such as mitochondrial dysfunction, abnormal protein aggregation, familial inheritance and excitotoxicity (18). A previous study demonstrated that CIQs, such as salsolinol and NM-salsolinol are promising endogenous neurotoxins that may lead to the development of PD (19).
Thus, a ‘vicious’ cycle may be induced by CIQs. ADTIQ is structurally similar to salsolinol, and has been suggested to be a neurotoxin (20,21).

Glycolysis is a crucial process in DM and the most extensively investigated metabolic pathway (22). MG is an important byproduct in this pathway and its production is increased due to hyperglycemia. The formation of dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate by fructose-1,6-bisphosphate is catalyzed by aldolase. Triosephosphate isomerase catalyzes aldoketose isomerization of these triosephosphates, and eventually only D-glyceraldehyde-3-phosphate follows the glycolytic pathway, by being converted into 1,3-bisphosphoglycerate in a reaction catalyzed by D-glyceraldehyde-3-phosphate dehydrogenase (23). However, triose phosphates are unstable molecules and L-elimination reactions of the phosphoryl group from the common 1,2-enediolate of both trioses may occur, leading to MG formation (24,25). This is a non-enzymatic, parametabolic reaction and therefore MG occurrence is an

<table>
<thead>
<tr>
<th>No.</th>
<th>Protein annotation</th>
<th>Database accession no.</th>
<th>Sequence coverage</th>
<th>Control group (%)</th>
<th>Diabetes group (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Hexokinase</td>
<td>1BG3A</td>
<td>12</td>
<td>0.21±0.05</td>
<td>0.51±0.03</td>
</tr>
<tr>
<td>2</td>
<td>Fructose-bisphosphate aldolase</td>
<td>ADRTA</td>
<td>7</td>
<td>0.33±0.01</td>
<td>0.72±0.01</td>
</tr>
<tr>
<td>3</td>
<td>Triosephosphate isomerase</td>
<td>TPI1_RAT</td>
<td>6</td>
<td>0.27±0.08</td>
<td>0.77±0.02</td>
</tr>
<tr>
<td>4</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase</td>
<td>DERTG</td>
<td>16</td>
<td>0.16±0.03</td>
<td>0.54±0.04</td>
</tr>
<tr>
<td>5</td>
<td>Phosphoglycerate mutase, brain form</td>
<td>PMGB</td>
<td>14</td>
<td>0.14±0.04</td>
<td>0.38±0.04</td>
</tr>
<tr>
<td>6</td>
<td>Enolase</td>
<td>ENOA</td>
<td>9</td>
<td>0.22±0.02</td>
<td>0.42±0.01</td>
</tr>
<tr>
<td>7</td>
<td>Pyruvate kinase</td>
<td>KPVI1</td>
<td>7</td>
<td>0.25±0.05</td>
<td>0.57±0.01</td>
</tr>
<tr>
<td>8</td>
<td>SOD</td>
<td>DSRTN</td>
<td>9</td>
<td>0.55±0.02</td>
<td>0.21±0.01</td>
</tr>
<tr>
<td>9</td>
<td>ATP synthase</td>
<td>ATPB_RAT</td>
<td>9</td>
<td>0.71±0.02</td>
<td>0.27±0.03</td>
</tr>
</tbody>
</table>

Compared with control group, the expression levels of the first seven genes (genes 1-7) were increased, while those of the last two genes (genes 8 and 9) were decreased significantly. Protein expression levels are expressed as the means ± SD of the percentage integrated peak area (%) of peptides. SOD, superoxide dismutase; ATP, adenosine triphosphate; SD, standard deviation.

Figure 5. Western blot analysis of the expression of adenosine triphosphate (ATP) synthase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). GAPDH content in the rats with diabetes mellitus (DM) was increased, while the content of ATP synthase was decreased compared with the control group. The results were consistent with the results obtained from proteomics analysis.

Figure 6. Formation of the neurotoxin 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in the abnormal glucose metabolism pathway. In this pathway, dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate are formed from fructose-1,6-bisphosphate catalyzed by aldolase. Triosephosphate isomerase catalyzes aldoketose isomerization of these triosephosphates. Triose 1,2-enediol-3-phosphate, as an intermediate between dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate, is an unstable molecule which converts into methylglyoxal. Methylglyoxal can also be formed from D-glyceraldehyde-3-phosphate catalyzed by methylglyoxal synthase. Methylglyoxal is an important byproduct which is increased due to hyperglycemia in the pathway. ADTIQ is produced when dopamine reacts with methylglyoxal.
unavoidable consequence of glycolytic metabolism (26). MG can also be formed from the leakage of the 1,2-enediolate intermediate in the active center of triosephosphate isomerase in a paracatalytic reaction (27). Consequently, ADTIQ is produced when DA reacts with MG (Fig. 6).

As previously demonstrated, reactive oxygen species (ROS) induced by high glucose levels are involved in neurotoxicity and mitochondrial-dependent apoptosis of both death receptor- and mitochondrial-dependent apoptosis of the nervous system (28). Antioxidants may be a therapeutic option for preventing cardiovascular damage in patients with DM. ROS has been shown to be involved in collagen-induced platelet activation and aggregation (29).

In the SH-SY5Y cell model of hyperglycemia, a large amount of free radicals was generated during the course of treatment with high glucose, consistent with the observation that ROS generation and elimination systems were imbalanced under hyperglycemic conditions. Intracellular ROS and hydroxyl radical accumulation induced lipid peroxidation (LPO) (30); thus, lipid molecules were consumed uninterruptedly, decreasing the amount of unsaturated fatty acid and affecting the fluidity of biological membranes (31). MG and other aldehydes react with proteins and enzymes, which cause them to lose their biological activity and lead to an abnormal metabolism. Specifically, MG reacts with DA to form ADTIQ, which confirms the hypothesis that CIQs induce a ‘vicious’ cycle of oxidative stress.

In the present study, compared with the control group, the ADTIQ levels in the brains of rats with diabetes were found to be significantly elevated (p<0.01). We also demonstrated that the levels of 7 key enzymes from the glycolytic pathway were increased significantly in the brains of rats with diabetes. More precisely, the expression levels of fructose-bisphosphate aldolase and triosephosphate isomerase were higher, suggesting that hyperglycemia enhanced the concentration of dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate, thus leading to an increase in MG and ADTIQ levels. When ADTIQ accumulated and reached a critical level, damaged neurons and induced oxidative stress and apoptosis. Our results also indicated that SOD and ATP synthase protein levels were significantly reduced in the rats with diabetes. SOD is a potent antioxidant enzyme which exerts its effects by scavenging ROS. There are data suggesting that elevated glucose levels serve as a causal link between the mitochondrial hyperglycemia-induced overproduction of superoxide and each of the three major pathways responsible for hyperglycemic vascular damage caused to endothelial cells (32,33). It has previously been demonstrated that the C-peptide has a preventative effect on neuronal hippocampal apoptosis in type 1 diabetes, although it does not have any effect on oxidative stress (34,35). These results indicate that hyperglycemic conditions may reduce the activity of SOD; however, the mechanisms involved remain unclear. The decreased levels of ATP synthase suggest that hyperglycemic conditions may induce mitochondrial dysfunction and thus lead to the apoptosis of neuronal cells. However, it is evident that multiple factors are involved in the progression from diabetes to PD.

In conclusion, the present study demonstrates that ADTIQ may be a type of endogenous neurotoxin and is found in the brains of rats with diabetes. We also provide evidence in support of the existence of a ‘vicious’ cycle of oxidative stress. The accumulation of ADTIQ in diabetes is an important factor in the connection between diabetes and PD.

Acknowledgements

The authors wish to acknowledge the financial support provided by the Ministry of Science and Technology of the People's Republic of China (grant nos. 2012YQ040140, 2009BAK59B01, 02 and 03) and the National Natural Science Foundation of China (grant no. 81202996).

References


